cal services include both level I and level II HCPCS codes for all non-ASP services. 4 Drug services therefore include drugs covered by Medicare Part B, which are typically those that must be administered at a physician's office or in an outpatient setting. 4 Medical services cover the remainder of HCPCS codes and range from biopsies to inpatient and outpatient visits, among other services. 4 Clinician urban status was determined by zip code according to CMS methods. 5 Continuous variables were reported as medians with interquartile ranges (IQRs) and compared using a KruskalWallis test, with significance set at 2-sided P < .05. For each study year, the Gini coefficient was calculated to represent changes in the level of inequality in Medicare payments to dermatologists. The Gini coefficient has previously been used to compare industry payments to physicians across different specialties as well as to compare industry payments to physicians within a given specialty. 6 Choropleth maps of average Medicare payment per dermatologist by zip code were produced using Tableau Public, version 2018.2 (Tableau Software). Calculations were performed using Microsoft Excel 2013 (Microsoft Corp) and STATA, version 13.1 (StataCorp).
Results
The number of dermatologists utilizing Medicare grew from 10 623 in 2012 to 11 279 in 2015, representing a 6.2% increase 7, 8 ( Table) . 5, 9 During this same period, the median (IQR) number Overall, all metrics associated with drug services significantly increased from 2012 to 2015 (P < .001 for all; Table) . Specifically, the median (IQR) number of drug services provided increased from 18 (0-78) to 27 (0-89) (P < .001), and the median (IQR) number of unique beneficiaries who received drug services increased from 12 (0-31) to 15 (0-36) (P < .001). In ad- (Table) .
The top half of dermatologists received disproportionate amounts of total Medicare payments in each year studied, with the 75th percentile receiving approximately 2 times the median payment, the 95th percentile receiving approximately 5 times the median payment, and the 99th percentile receiving approximately 10 times the median payment for all years. The Gini coefficient revealed a moderate and stable level of inequality for payments between 2012 (0.544) and 2015 (0.544). Payments were concentrated in urban and metropolitan areas (Figure) .
Discussion
Our findings reveal increased Medicare utilization by dermatologists from 2012 to 2015, with a corresponding increase in submitted charges but no reciprocal increase in the amounts allowed or paid by Medicare. Although the total number of Medicare beneficiaries increased by 9.2% from 50 828 094 in 2012 to 55 504 005 in 2015, 10 there was no change in the number of unique beneficiaries or the number of services provided by dermatologists during this same period. These findings should be interpreted in the context of legislation such as the Budget Control Act of 2011, which was newly implemented during the study period and subjected Medicare payments to automatic reductions (up to 2%) beginning in 2013. 11 Our findings suggest that there may already be tangible short-term effects 3 years after its implementation. One possible explanation for these findings is that cuts to Medicare physician payments may have affected Medicare patients' access to dermatologists. Although access and wait times do not differ between Medicare and private insurance on a national level, regional "hot spots" have higher rates of Medicare refusal and longer wait times. 12 These hot spots are char- acterized by lower Medicare payments relative to commercial insurance payments. 12 The increase in total submitted charges with no increase in services per clinician or number of beneficiaries may represent increased billing in response to these payment trends. Consistent with the above findings, physicians of other specialties have also reported low reimbursement as a reason for opting out of Medicare.
13
Although we did not observe a significant shift in the geographic location of dermatologists, gradual microshifts in the concentration of dermatologists toward urban areas may also help explain increased Medicare utilization and submitted charges per clinician with no increases in services per clinician or number of beneficiaries. This is consistent with an earlier study showing increased Medicare utilization in dermatologist-dense areas. Although the authors found a correlation between dermatologist density and both the total number of procedures and the mean amount billed per patient, average billing on a per-dermatologist basis actually decreased with increasing density.
14 As dermatologists cluster in urban areas, the number of services provided by an individual dermatologist to a limited Medicare beneficiary pool may be kept constant by competition between physicians. The increase in submitted charges per clinician observed in our data may not have been present in the earlier study owing to the inclusion of dermatologists who chose not to accept patients who use Medicare. When separating medical and drug services payments to dermatologists, we found that all metrics associated with drug services significantly increased between 2012 and 2015. Although dermatologists provide a number of services that fall under the CMS definition of drug services, the 2 largest by count are consistently triamcinolone injections and topical aminolevulinic acid administration. Aminolevulinic acid is well recognized for its use in photodynamic therapy (PDT) as a treatment for actinic keratoses, cutaneous neoplasms, and other conditions. 7 Notably, the use of PDT billing codes for Medicare patients increased 5% annually from 2000 to 2015, with dermatologists accounting for 92% of PDT volume between 2012 and 2015. 8 Given the variety of modalities and increasing number of indications, PDT may be a key driver for the observed increase in drug services metrics.
Limitations
The primary limitation of our study is the limited period of available Medicare utilization and payment data. In addition, this data set did not report the insurance composition of individual practices, nor did it specify whether the amounts included billing by physician extenders. Both of these information gaps make it difficult to accurately analyze a dermatologist's entire practice activity.
Conclusions
Our findings suggest that current trends in Medicare payments to dermatologists may affect patient access. Although the number of dermatologists currently opting out of Medicare is low, it is important to consider how Medicare payments can be optimized to maintain dermatologist access across the entire Medicare population. 
